We are live on ! Find out more

ATHE

Alterity Therapeutics

ATHE

Market cap $71.2M

3.91 USD

+0.16

4.27%

At close Updated Sep 18, 4:00 PM EDT

1 day

4.27%

5 days

-2.74%

1 month

-14.25%

3 months

-19.88%

6 months

11.71%

Year to date

23.73%

1 year

-10.73%

5 years

-69.21%

10 years

-92.18%

About: Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.

Employees: 11

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States.

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential –

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference

MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the 46th Annual Canaccord Genuity Growth Conference on Tuesday, August 11, 2026 at 1:30 p.m. ET in the United States.

Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA Pivotal Phase 3 trial activities on track to initiate by year-end 2026 Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value Peer-reviewed publication in NeuroImage validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA Strengthened the Board of Directors with the appointment of Ms Ann Cunningham A$3.98 million Australian R&D Tax Incentive refund received subsequent to quarter end, supporting continued development of Alterity's clinical programs Cash balance of A$37.3 million as at 30 June 2026 MELBOURNE, Australia and SAN FRANCISCO, July 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2026 (Q4 FY26). “This was a defining quarter for Alterity, highlighted by our positive End of Phase 2 meeting with the FDA that established a clear, efficient registrational pathway for ATH434,” said David Stamler, M.D.

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in the BTIG Biotechnology Conference 2026 taking place virtually 28-29 July 2026.

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol —

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday's session as the biotechnology company announced an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its pivotal Phase 3 program for ATH434 in treating Multiple System Atrophy (MSA).

Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration –

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) –

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

See News Rankings

Price charts implemented using Lightweight Charts™